The article you requested is
Academic Highlights: The Pharmacologic Rationale for the Clinical Use of Antidepressants
J Clin Psychiatry 1997;58:501-508
Copyright 1997 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($129) or print + online ($166 individual).
- Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
Mirtazapine is the latest in a line of
drugs that have recently been introduced
for the treatment of depression.
It is now available worldwide and has
been used in more than 170,000 patients
(May 1997). The novelty of this
drug over other antidepressants lies
particularly in its unique mechanism
Mirtazapine inhibits neither the
reuptake of norepinephrine (NE), serotonin
(5-HT), or dopamine (DA) nor
the activity of monoamine oxidase,
thereby clearly being distinguished
from the tricyclic antidepressants
(TCAs), newer reuptake inhibitors of
either serotonin and/or norepinephrine
(SSRI/SNRI), and the monoamine oxidase